Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Gross Profit (2020 - 2025)

Historic Gross Profit for BridgeBio Pharma (BBIO) over the last 6 years, with Q3 2025 value amounting to $114.1 million.

  • BridgeBio Pharma's Gross Profit rose 524850.05% to $114.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $338.8 million, marking a year-over-year increase of 5732.75%. This contributed to the annual value of $218.0 million for FY2024, which is 307958.29% up from last year.
  • As of Q3 2025, BridgeBio Pharma's Gross Profit stood at $114.1 million, which was up 524850.05% from $106.9 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Gross Profit ranged from a high of $210.5 million in Q1 2024 and a low of -$2.4 million during Q4 2021
  • Its 5-year average for Gross Profit is $37.7 million, with a median of $2.1 million in 2024.
  • As far as peak fluctuations go, BridgeBio Pharma's Gross Profit crashed by 14505.62% in 2022, and later surged by 1781676.6% in 2024.
  • Over the past 5 years, BridgeBio Pharma's Gross Profit (Quarter) stood at -$2.4 million in 2021, then surged by 151.36% to $1.2 million in 2022, then dropped by 6.21% to $1.1 million in 2023, then soared by 231.12% to $3.8 million in 2024, then surged by 2905.19% to $114.1 million in 2025.
  • Its Gross Profit was $114.1 million in Q3 2025, compared to $106.9 million in Q2 2025 and $114.0 million in Q1 2025.